Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Vomiting 31Nausea 27Neoplasms 14Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 7Multiple Myeloma 6Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Burkitt Lymphoma 5Sezary Syndrome 4Primary Myelofibrosis 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Hairy Cell 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, Large-Cell, Anaplastic 3

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Ondansetron × Clear all
NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡